Cross-Reactive and Cross-Neutralizing Activity of Human Mumps Antibodies Against a Novel Mumps Virus From Bats
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissionsoup.com..
To evaluate the antigenic relationship between bat mumps virus (BMV) and the JL5 vaccine strain of mumps virus (MuVJL5), we rescued a chimeric virus bearing the F and HN glycoproteins of BMV in the background of a recombinant JL5 genome (rMuVJL5). Cross-reactivity and cross-neutralization between this chimeric recombinant MuV bearing the F and HN glycoproteins of BMV (rMuVJL5-F/HNBMV) virus and rMuVJL5 were demonstrated using hyperimmune mouse serum samples and a curated panel of human serum. All mouse and human serum samples that were able to neutralize rMuVJL5 infection had cross-neutralizing activity against rMuVJL5-F/HNBMV. Our data suggest that persons who have neutralizing antibodies against MuV might be protected from infection by BMV.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:215 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 215(2017), 2 vom: 15. Jan., Seite 209-213 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Beaty, Shannon M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.06.2017 Date Revised 29.01.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiw534 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM265906997 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM265906997 | ||
| 003 | DE-627 | ||
| 005 | 20231224213325.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiw534 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0886.xml |
| 035 | |a (DE-627)NLM265906997 | ||
| 035 | |a (NLM)27811320 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Beaty, Shannon M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cross-Reactive and Cross-Neutralizing Activity of Human Mumps Antibodies Against a Novel Mumps Virus From Bats |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.06.2017 | ||
| 500 | |a Date Revised 29.01.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissionsoup.com. | ||
| 520 | |a To evaluate the antigenic relationship between bat mumps virus (BMV) and the JL5 vaccine strain of mumps virus (MuVJL5), we rescued a chimeric virus bearing the F and HN glycoproteins of BMV in the background of a recombinant JL5 genome (rMuVJL5). Cross-reactivity and cross-neutralization between this chimeric recombinant MuV bearing the F and HN glycoproteins of BMV (rMuVJL5-F/HNBMV) virus and rMuVJL5 were demonstrated using hyperimmune mouse serum samples and a curated panel of human serum. All mouse and human serum samples that were able to neutralize rMuVJL5 infection had cross-neutralizing activity against rMuVJL5-F/HNBMV. Our data suggest that persons who have neutralizing antibodies against MuV might be protected from infection by BMV | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a cross-reactive antibodies | |
| 650 | 4 | |a mumps virus | |
| 650 | 4 | |a neutralizing antibodies | |
| 650 | 4 | |a viral envelope proteins | |
| 650 | 4 | |a zoonoses | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Nachbagauer, Raffael |e verfasserin |4 aut | |
| 700 | 1 | |a Hirsh, Ariana |e verfasserin |4 aut | |
| 700 | 1 | |a Vigant, Frederic |e verfasserin |4 aut | |
| 700 | 1 | |a Duehr, James |e verfasserin |4 aut | |
| 700 | 1 | |a Azarm, Kristopher D |e verfasserin |4 aut | |
| 700 | 1 | |a Stelfox, Alice J |e verfasserin |4 aut | |
| 700 | 1 | |a Bowden, Thomas A |e verfasserin |4 aut | |
| 700 | 1 | |a Duprex, W Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Krammer, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Benhur |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 215(2017), 2 vom: 15. Jan., Seite 209-213 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:215 |g year:2017 |g number:2 |g day:15 |g month:01 |g pages:209-213 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiw534 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 215 |j 2017 |e 2 |b 15 |c 01 |h 209-213 | ||